Chemoradiation in Cervical Cancer with Cisplatin and High-Dose Rate Brachytherapy Combined with External Beam Radiotherapy

Strauß, Hans‐Georg; Kuhnt, Thomas; Laban, Cornelia; Puschmann, Daniela; Pigorsch, Steffi; Dunst, Juergen; Koelbl, Heinz; Haensgen, G.

doi:10.1007/s00066-002-0956-1

Cited by 50 publications

(35 citation statements)

References 22 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…52 A total of eight studies have used chemotherapy with HDR and reported toxicity. Three were single-arm retrospective analyses in which all patients received chemo-radiation [53][54][55] ; 3 retrospectively compared patients treated with and without chemotherapy [56][57][58] ; 2 present prospectively collected data. 52,59 None of these studies shows a significant difference in Grades 3 and 4 gastrointestinal and genitourinary late complications (Table 4).…”

Section: Chemotherapymentioning

confidence: 99%

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Stewart¹,

Viswanathan²

2006

Cancer

View full text Add to dashboard Cite

The use of brachytherapy in the treatment of cervical cancer has increased worldwide since its initial introduction over 100 years ago. However, certain aspects of the use of high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy continue to be controversial, particularly the role of HDR in FIGO Stage III cervical cancer and the use of HDR with concurrent chemotherapy. This study represents a systematic literature review of prospective and retrospective series of patients with cervical carcinoma treated with external-beam radiation

show abstract

Section: Chemotherapymentioning

confidence: 99%

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Stewart¹,

Viswanathan²

2006

Cancer

View full text Add to dashboard Cite

show abstract

“…Compared with Strauss et al [24]. A complete response and disease free survival were 88% and 75% vs., 92.3% and 80% respectively.…”

Section: Discussionmentioning

confidence: 61%

“…Strauss et al treated 27 patients with stage IIB-IIIB cervical cancers with concurrent Cisplatin and brachytherapy in Germany [24]. Complete response rate was 92.3%, and 80% of the patients were disease free in 20 months follow-up.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Role of Concurrent Chemotherapy and Brachytherapy in Locally Advanced Cervical Cancer Patients

Singh¹,

Jain²

2016

J Cancer Sci Ther

View full text Add to dashboard Cite

Aim: Carcinoma of Uterine cervix is the commonest cancer affecting females in developing countries. Concurrent chemoradiation has remained the sole definitive treatment available in the advanced stages. The study was planned to take the advantage of radiosensitisation accruing due to chemotherapy at the time of brachytherapy, when approximately forty percent of total tumor dose is applied. Materials and methods:64 patients were enrolled who had locally advanced uterine cervix carcinoma (FIGO stage IIB to IVA) from July 2011 to May 2013 for concurrent chemotherapy and intracavitory brachytherapy after completion of concurrent chemotherapy and external beam radiotherapy followed by 3 insertion of brachytherapy separated by a week by Flexitron brachytherapy unit to point A, for each application was 6 Gy by HDR. Cisplatin was given (35 mg/m 2 ) one day before brachytherapy in each application. Results:At medium follow-up of 19 months (range 8 to 30 months) clinical complete response rate was found to be 89% at 3 months of follow up. Acute side effect as nausea and vomiting grade I and II were recorded as 55% and 28% respectively, no renal dysfunction and no thrombocytopenia were encountered. No patients had grade IV or life threatening toxicity. Overall survival and disease free survival after 30 months of follow up is 88% and 75% respectively. Conclusion:Use of concurrent chemotherapy with brachytherapy is effective and feasible with acceptable toxicity for locally advanced carcinoma of the uterine Cervix.

show abstract

“…In 2003, the same authors have published a systematic review of the concurrent treatment toxicity which describes a significant increase, especially in grade 3 and 4 gastrointestinal and hematological toxicity, with a twofold increase in white blood cell toxicity and threefold increase of platelet toxicity (6). This review, as well as several recently published studies, has described leukopenia as the most common form of acute toxicity in concurrent chemoradiotherapy with cisplatin (10,15,17,19). Our study has confirmed these results, as we have noted the acute hematological toxicity in 95 % of patients, predominantly grade 2 and 3.…”

Section: Discussionmentioning

confidence: 99%

The Influence of Cisplatin Dose upon Survival in Concurrent Chemoradiotherapy of Locally Advanced Cervical Carcinoma with Weekly Cisplatin

Sirák

Petera

Zoul

2008

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

The objective of this study was to evaluate the influence of cisplatin dose upon 3-year overall and disease-free survival rate of patients with advanced cervical cancer treated with concurrent chemoradiotherapy with weekly cisplatin. Seventy-three patients with stage IIB – IVA cervical carcinoma were treated with pelvic (or pelvic + paraaortic) externalbeam radiotherapy, high-dose rate brachytherapy and concomitant chemotherapy with weekly cisplatin of 40 mg/m2 in the time period form January 2000 to December 2006 at our department. The 3-year overall survival and disease-free suvival rates were evaluated with regard to the number of cisplatin cycles applied during the external radiotherapy. Only twentyeight patients received the intended five doses of chemotherapy. The most frequent cause of chemotherapy delay was the acute hematological toxicity with leukopenia. The 3-year overall survival was 71 % and the 3-year disease-free survival was 61 %. Survival analyses didn’t prove a statistically significant influence of cisplatin dose upon 3-year survival in cervical carcinoma patients treated by exclusive chemoradiation with weekly cisplatin.

show abstract

Chemoradiation in Cervical Cancer with Cisplatin and High-Dose Rate Brachytherapy Combined with External Beam Radiotherapy

Abstract: Concomitant chemoradiation with cisplatin 40 mg/m2 weekly x 6 using HDR brachytherapy represents a promising treatment of cervical cancer with an acceptable toxicity.

Cited by 50 publications

References 22 publications

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Evaluation of Role of Concurrent Chemotherapy and Brachytherapy in Locally Advanced Cervical Cancer Patients

The Influence of Cisplatin Dose upon Survival in Concurrent Chemoradiotherapy of Locally Advanced Cervical Carcinoma with Weekly Cisplatin

Contact Info

Product

Resources

About